Differences between WHO AND CDC early growth measurements in the assessment of Cystic Fibrosis clinical outcomes.
Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial.
FAM13A is a modifier gene of cystic fibrosis lung phenotype regulating rhoa activity, actin cytoskeleton dynamics and epithelial-mesenchymal transition
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
Lung Function Decline is Delayed But Not Decreased in Patients With Cystic Fibrosis and the R117H Gene Mutation
Bile salt stimulated lipase, Cystic fibrosis, Enzyme therapy, NMR spectroscopy, Pancreatic insufficiency, Titrimetric enzyme assay
